Talk:Triple releasing agent: Difference between revisions

Line 1:

'''Triple releasing agent (TRA)''', also known as a ('''serotonin-norepinephrine-dopamine releasing agent (SNDRA)'''), is a type of psychoactive substance that induces the release of four major central nervous system [[monoamine]] neurotransmitters, [[serotonin]], [[norepinephrine]], [[epinephrine]], and [[dopamine]], in the body and/or brain. Triple releasing agents are known to typically produce [[Euphoria|euphoriant]], [[entactogen]], and [[stimulant]] effects, and are almost exclusively encountered in the context of [[recreational drug use]].

A closely related type of substance is a '''triple reuptake inhibitor (TRI)''', which also typically produce an increase in synaptic concentrations of the above-mentioned monoamines, albeit through a different mechanism. Unlike triple releasing agents, triple reuptake inhibitors have been investigated for various potential medical uses<ref>Chen, Z., & Skolnick, P. (2007). Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opinion on Investigational Drugs, 16(9), 1365-1377. http://dx.doi.org/10.1517/13543784.16.9.1365</ref> and FDA approval has been granted for the use of one such compound as an antidepressant,{{citation needed}} and for the use of several others as [[Appetite suppression|anorectics]].{{citation needed}} Other triple reuptake inhibitors see widespread use as [[recreational drugs]], with [[cocaine]] being a prominent example.

A closely related type of substance is a '''triple reuptake inhibitor (TRI)''', which also typically produce an increase in synaptic concentrations of the above-mentioned monoamines, albeit through a different mechanism. Unlike triple releasing agents, triple reuptake inhibitors have been investigated for various potential medical uses<ref>Chen, Z., & Skolnick, P. (2007). Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opinion on Investigational Drugs, 16(9), 1365-1377. http://dx.doi.org/10.1517/13543784.16.9.1365</ref> and FDA approval has been granted for the use of one such compound as an antidepressant,{{citation needed}} and for the use of several others as [[Appetite suppression|anorectics]].{{citation needed}} Other triple reuptake inhibitors see widespread use as [[recreational drug use|recreational drugs]], with [[cocaine]] being a prominent example.

==Neurotoxicity==

@@ Line 1: / Line 1: @@
 '''Triple releasing agent (TRA)''', also known as a  ('''serotonin-norepinephrine-dopamine releasing agent (SNDRA)'''), is a type of psychoactive substance that induces the release of four major central nervous system [[monoamine]] neurotransmitters, [[serotonin]], [[norepinephrine]], [[epinephrine]], and [[dopamine]], in the body and/or brain. Triple releasing agents are known to typically produce [[Euphoria|euphoriant]], [[entactogen]], and [[stimulant]] effects, and are almost exclusively encountered in the context of [[recreational drug use]].
-A closely related type of substance is a '''triple reuptake inhibitor (TRI)''', which also typically produce an increase in synaptic concentrations of the above-mentioned monoamines, albeit through a different mechanism. Unlike triple releasing agents, triple reuptake inhibitors have been investigated for various potential medical uses<ref>Chen, Z., & Skolnick, P. (2007). Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opinion on Investigational Drugs, 16(9), 1365-1377. http://dx.doi.org/10.1517/13543784.16.9.1365</ref> and FDA approval has been granted for the use of one such compound as an antidepressant,{{citation needed}} and for the use of several others as [[Appetite suppression|anorectics]].{{citation needed}} Other triple reuptake inhibitors see widespread use as [[recreational drugs]], with [[cocaine]] being a prominent example.
+A closely related type of substance is a '''triple reuptake inhibitor (TRI)''', which also typically produce an increase in synaptic concentrations of the above-mentioned monoamines, albeit through a different mechanism. Unlike triple releasing agents, triple reuptake inhibitors have been investigated for various potential medical uses<ref>Chen, Z., & Skolnick, P. (2007). Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opinion on Investigational Drugs, 16(9), 1365-1377. http://dx.doi.org/10.1517/13543784.16.9.1365</ref> and FDA approval has been granted for the use of one such compound as an antidepressant,{{citation needed}} and for the use of several others as [[Appetite suppression|anorectics]].{{citation needed}} Other triple reuptake inhibitors see widespread use as [[recreational drug use|recreational drugs]], with [[cocaine]] being a prominent example.
 ==Neurotoxicity==